Table 1 Clinical/pathological characteristics of the study population (n = 45)
Characteristics | No (%) |
|---|---|
Histotype | Â |
   Serous | 33 (76.7) |
   Endometrioid | 3 (7.0) |
   Clear cell | 2 (4.6) |
   Undifferentiated | 3 (7.0) |
   Other | 4 (8.9%) |
Grade | Â |
   G1-2 | 7 (19.4) |
   G3 | 29 (80.6) |
   n.a. | 9 |
First line Chemotherapy | Â |
   Platinum-based | 8 (17.8) |
   Platinum/taxane-based | 37 (82.2) |
Platinum sensitivity | Â |
   Primary refractoriness | 4 (8.9) |
   Primary resistance | 9 (20.0) |
   Secondary resistance | 10 (22.2) |
   Relative sensitivity | 22 (48.9) |
No. previous chemotherapy lines for recurrence treatment | Â |
   1 | 6 (13.3) |
   2 | 12 (26.7) |
   3 | 19 (42.2) |
   ≥4 | 8 (17.7) |
No. previous platinum-based re-challenges | Â |
   None | 25 (55.5) |
   1 | 17 (37.8) |
   2 | 3 (6.7) |
Age, years | Â |
   Median (range) | 59 (34-74) |
ECOG PS | Â |
   0 | 20 (44.4) |
   1 | 23 (51.1) |
   2 | 2 (2.5) |